FDA approves a new beta blocker

Dec 18, 2007

The U.S. Food and Drug Administration has approved Bystolic, a beta blocker, for the treatment of high blood pressure. Bystolic (nebivolol) is a new drug not previously approved for use in the United States.

Beta blockers are a well-established class of medications that reduce blood pressure by reducing the force with which the heart pumps, the FDA said. Nearly 1-in-3 adults in the United States suffers from hypertension, which can increase the risks for stroke, heart failure, heart attack, kidney failure, and death.

The FDA said the safety and efficacy of Bystolic was assessed during three randomized, double-blind, multi-center, placebo-controlled clinical trials that ran for up to three months. A fourth placebo-controlled clinical trial demonstrated additional blood pressure-lowering effects when Bystolic was given with up to two other antihypertensive medications in patients with inadequate blood pressure control.

More than 2,000 people received Bystolic during the trials, the FDA said, with the most common side effects reported being headache, fatigue, dizziness and diarrhea.

Mylan Bertek Pharmaceuticals Inc. of Research Triangle Park, N.C., is the sponsor of Bystolic. New York City-based Forest Laboratories Inc. owns the rights for marketing of the drug.

Copyright 2007 by United Press International

Explore further: Expression of privilege in vaccine refusal

add to favorites email to friend print save as pdf

Related Stories

Amazing raw Cassini images from this week

52 minutes ago

When Saturn is at its closest to Earth, it's three-quarters of a billion miles away—or more than a billion kilometers! That makes these raw images from the ringed planet all the more remarkable.

Researchers look at small RNA pathways in maize tassels

1 hour ago

Researchers at the University of Delaware and other institutions across the country have been awarded a four-year, $6.5 million National Science Foundation grant to analyze developmental events in maize anthers ...

Proteins: New class of materials discovered

1 hour ago

Scientists at the Helmholtz Center Berlin along with researchers at China's Fudan University have characterized a new class of materials called protein crystalline frameworks.

Recommended for you

Most US babies get their vaccines, CDC says

14 hours ago

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments : 0